comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 10:04:09 - browse：8836

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： STAT Readout: Friday, Oct. 20 biotech updates

knowledge

WSS

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

4th of July breaks record for highest global temperature ever measured

FDA clears Verve to begin U.S. study of gene

Why is France rioting? What to know about the fatal police shooting of Nahel M

4th of July breaks record for highest global temperature ever measured

hotspot

comprehensive

focus

Hollywood unions extend contract negotiations for actors

RaDonda Vaught case: a double standard for nurses, physicians

Psychedelics group wrestles with new pharma identity

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Medical records are filled with copy

RaDonda Vaught case: a double standard for nurses, physicians

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

knowledge

STAT Readout Newsletter: Biotech news today

Why is France rioting? What to know about the fatal police shooting of Nahel M

STAT Readout Newsletter: Biotech news today

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Meghan O’Rourke on making chronic illness visible

Grail is spending more than ever lobbying Congress

knowledge

hotspot

hotspot

leisure time